Zoetis falls after quarterly beat but cautious planning for 2027

What happened

Zoetis (ZTS) fell 7.9% on November 5, 2026, because of quarterly results that beat estimates but included cautious planning for 2027. The stock opened 4.9% below the previous close and finished the session at $82.11 as trading volume ran 2.3 times its 20-day average. The S&P 500 fell 4.4% on the day and the healthcare sector median fell 5.7%, but the stock’s decline was 2.3 percentage points worse than the sector median.

How big was the move

The sell-off was 3.5 times a typical daily move for this stock and larger than the typical two-day reaction after recent reports, which fell 7.0%. The stock’s market sensitivity is a beta of 0.35, meaning the stock tends to move less than the market, yet it still fell more sharply than both the index and its sector that day. Over the last five sessions the stock rose 4.2%, even as the S&P 500 over five sessions fell 4.7%, so the single-session drop represented a reversal from a short-term advance.

The technical picture

The stock sat 3.1% above its 20-day moving average and 8.6% above its 50-day moving average, while it remained 11.4% below its 200-day moving average. The 50-day average is below the 200-day average, a sign of a weak longer-term trend. The Relative Strength Index (14 days) stands at 57, in a neutral range between 30 and 70. Over one month the stock rose 14.8% and over three months it rose 13.0%, but over one year it fell 34.0% and sits 38.0% below the 52-week high. Volatility is 36% annualized over 60 days, higher than 87% of its own readings over five years.

Fundamentals and valuation

For the four quarters through September 30, 2026, Zoetis reported revenue of $9.51 billion, which grew 1.2% from a year earlier, and diluted earnings per share of $5.88, with earnings per share growth from a year earlier fell 1.0%. Gross margin was 71.0% (a year earlier: 70.3%) and operating margin was 37.0% (a year earlier: 37.6%). The company reported a free-cash-flow margin of 24.0% and return on invested capital of 21.6%. Its balance sheet shows net cash of $1.15 billion, and share count over one year decreased by 7.1%.

Those results point to durable profitability and strong cash generation even as top-line growth is modest. Valuation sits at 14.0 times trailing earnings and 13.2 times expected earnings on a price to forward earnings basis. The price to trailing earnings is lower than 90% of its own readings over the past five years (five-year median: 32.7 times earnings), which helps explain the market reaction: investors priced the stock on slower growth despite healthy margins. Free-cash-flow yield is 6.9% and PromtFinance scores rank the stock highly on Value at 94 (Exceptional) and Quality at 86 (Strong), while Growth is 29 (Very weak) and Revisions are 15 (Very weak).

Earnings and analyst expectations

Zoetis reported third-quarter 2026 results that beat consensus on both revenue and adjusted EPS, with adjusted earnings of $1.75 per share versus a consensus of $1.51, 15.9% above estimates, according to Business Wire and Benzinga. The company said organic operational revenue was down 1% year-over-year while global livestock revenue rose to $797 million. Management narrowed full-year 2026 revenue guidance while raising full-year 2026 adjusted EPS guidance. The next report is scheduled for February 11, 2027.

The stock has recorded consecutive quarters beating estimates of 2 and an average surprise over the last four reports of 4.6% above estimates. Analysts’ consensus rating is Hold; 44% of the 32 analysts with a rating assign Buy or Strong Buy and the consensus price target is $84.75, 3.2% above the closing price.

Reuters reported that Zoetis signalled cautious planning for 2027, citing reduced vet visits as pet owners cut back, a development that contributed to the decline in the company’s shares. That outlook appears to have outweighed the company’s solid profitability metrics and its abundant free cash flow in investors’ near-term calculus.

What to watch

• Next report: February 11, 2027
• Last report: November 5, 2026: earnings per share of $1.75 against $1.51 expected, 15.9% above estimates
• Market value: $32.94 billion
• Price to trailing earnings: 14.0 times trailing earnings
• Free-cash-flow margin: 24.0%